Dominant B cell epitopes and methods of making and using thereof
View Patent ↗Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof.
1. An isolated polypeptide consisting of SEQ ID NO:3.
2. A composition comprising the isolated polypeptide of claim 1 .
3. A substrate which comprises the isolated polypeptide of claim 1 immobilized thereon.
4. A kit comprising the isolated polypeptide of claim 1 packaged together with at least one reagent.
5. A complex comprising the isolated polypeptide of claim 1 and an antibody which selectively binds the polypeptide.
6. A method for assaying, enriching, isolating or purifying at least one antibody, against a tumor associated antigen or a B cell secreting the antibody, which comprises contacting the antibody with the isolated polypeptide of claim 1 .
7. A method which comprises contacting the isolated polypeptide of claim 1 with a sample and detecting whether an antibody in the sample selectively binds the polypeptide.
8. A method for detecting, diagnosing, or monitoring a cancer in a subject which comprises contacting the isolated polypeptide of claim 1 with a sample obtained from the subject and detecting whether an antibody in the sample selectively binds the polypeptide.
9. The method of claim 8 , wherein the cancer expresses a NY-ESO-1 tumor associated antigen.
10. The method of claim 8 , wherein the cancer is melanoma, prostate cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, bladder cancer, ovarian cancer, breast cancer, testicular cancer, prostate cancer, myeloma, small cell lung cancer or sarcoma.
11. The method of claim 8 , wherein a plurality of samples obtained from the subject are tested.
12. The method of claim 11 , wherein the plurality of samples are obtained before, during or after treating the cancer.
13. The method of claim 12 , wherein the regression, recurrence or progression of the cancer is determined by observing any change or difference in the antibody selectively binding the polypeptide from the plurality of samples.